^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Yutuo (zimberelimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LIGAND’S PARTNER GLORIA BIOSCIENCES RECEIVES APPROVAL IN CHINA FOR ZIMBERELIMAB FOR THE TREATMENT OF RECURRENT OR REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
Published date:
08/30/2021
Excerpt:
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
